|
SGLT2i Uptake Disparities, Heartflow’s DECIDE, and Unethical Organ Harvesting
July 28, 2025
|
|
|
|
|
Together with
|
|
|
|
“Many doctors have bemoaned their loss of professional autonomy. What AI is likely to bring could be far worse for some doctors — extinction.”
|
|
John Mandrola, MD introducing Edward J. Schloss, MD’s editorial in Sensible Medicine.
|
|
|
Cardiology Pharmaceuticals
|
|
|
|
|
|
Three years after SGLT2 inhibitors were added to the heart failure treatment guidelines, a JAMA Cardiology study reveals significant new prescriptions, with a few key patient sub-groups falling behind.
- SGLT2 inhibitors promote the excretion of sodium and glucose in the urine, which can help reduce fluid overload and improve heart function in HF patients.
- While the benefits of SGLT2is are seen across the HF spectrum, they are most established in HFrEF.
Researchers analyzed prescribing patterns of SGLT2 inhibitors for 760k HF patients in the National Cardiovascular Data Registry and found significant and rapid uptake in the last three years.
- Uptake occurred within 3 years of FDA approval for HFrEF and 1 year for HFpEF.
- SGLT2 inhibitor prescribing for all heart failure patients increased from 4.6% to 16.2% between 2019-2023.
- Breaking that down by HF subtypes, HFrEF patients saw increases from 5.1% to 28.5%, while HFmrEF/HFpEF patients increased from 4.5% to 12.8%.
However, despite the early success, researchers also uncovered some concerning disparities across patient types that were less likely to receive prescriptions such as…
- Women (aOR: 0.79).
- Older patients (aOR: 0.76).
- Patients with higher blood pressure (aOR 0.78).
Beyond the patient sub-group disparities, the study also noted that there was significant variation across 191 U.S. sites, ranging from 2% to 60% prescribing rates even after adjusting for patient and practice characteristics.
The Takeaway
Heart failure is undoubtedly one of the hardest cardiovascular conditions to treat, and while more and more pharmaceutical options are becoming available, it’s clear we have a long way to go before they’re widely accepted by physicians across the board. On the bright side, this study suggests SGLT2i’s are headed in the right direction.
|
|
Explore Vitrea Advanced Visualization
Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow
|
|
Heartflow Roadmap Analysis For Efficient Care
As Coronary CT scan volumes increase, your entire reading team needs to deliver efficient and consistent reads. Good thing Heartflow’s Roadmap Analysis can help you maintain accuracy and increase CCTA read speeds by up to 25%, with even level 3 readers seeing real efficiency benefits.
|
|
Us2.ai’s Echo Automation Impact
Improving clinician efficiency and quality is the goal for most AI solutions, but we rarely see AI achieve both. See how the AI-ECHO RCT used Us2.ai to achieve both of those goals, while reducing sonographer fatigue in the process.
|
|
- Heartflow Helps Physicians DECIDE: Results from Heartflow’s DECIDE Registry study suggest its AI-enabled Plaque Analysis software significantly changes patient care decisions. The study examined 20k patients across the U.S. and found that the CCTA-based Plaque Analysis software led to medical management changes in over half of patients beyond traditional CCTA scans alone. Applying the technology also resulted in an average 18.7mg/dL decrease in LDL-C and a 15% lower cardiac event risk. Unlike CCTA-alone that often misses non-calcified plaque, Heartflow’s AI quantifies all plaque types to help clinicians personalize treatment plans.
- AI for LV Dysfunction Detection: Researchers developed an AI algorithm to identify left ventricular dysfunction using routine echocardiographic measurements. The AI was tested on 81k patients and ranked them based on LV function, with the lowest dysfunction patients facing low 5-year mortality risks (2.3% for women, 5.7% for men), and the highest dysfunction patients facing far higher mortality risks (64.2% for men, and 66.3% for women). Importantly, the AI reliably identified clinically meaningful dysfunction even in patients with preserved ejection fraction and missing parameters.
- AHA’s Inflammation Detection Competition: The AHA launched a nationwide research competition to understand how inflammation contributes to cardiovascular risk. Funded partly by Novo Nordisk, the Systemic Inflammation Data Challenge offers $75k in prizes to teams using analytic software and electronic medical records to study systemic inflammation’s impact on heart disease. The challenge specifically focuses on high-sensitivity C-reactive protein testing, treatment disparities, and anti-inflammatory strategies like statins and colchicine.
- The First ECG AI Marketplace: Philips launched its ECG AI Marketplace to centralize multiple vendors’ AI algorithms for cardiac care teams. The platform aims to streamline AI workflow integration, while reducing IT costs and management complexity. Anumana is the Marketplace’s first partner, offering its FDA-cleared ECG-AI Low Ejection Fraction algorithm that detects heart failure indicators from 12-lead ECGs. With over 25 FDA-cleared ECG algorithms available on the market, Philips’ marketplace could help address growing demand for accessible AI while supporting earlier disease detection.
- Gapfill for Cardio Diagnostics: The CMS’ MolDX program issued preliminary gapfill payment rates for Cardio Diagnostics’ cardiovascular tests ($350 for Epi+Gen CHD and $684.76 for PrecisionCHD), effective January 1, 2025. Cardio Diagnostics’ tests analyze genetic and epigenetic markers from blood draws to diagnose CHD and assess three-year risk. With cardiovascular disease being the leading cause of death in the U.S., these Medicare payment rates show progress toward expanding cardiovascular testing.
- Venous Diseases are Common: The SAGE GROUP published a report quantifying chronic venous disease prevalence from 2020-2040, revealing that the disease affects 1.5 times more people than all other cardiovascular diseases combined and five times more than diabetes. Despite being highly prevalent, chronic venous disease remains underestimated, underdiagnosed, and undertreated. The most severe form, chronic venous insufficiency, increases all-cause mortality risk threefold. Over two million Americans suffered from venous ulcers in 2025, generating $55-70B in direct medical costs, with many cases underestimated due to self-treatment.
- Rocket’s 5th RMAT: Rocket Pharmaceuticals announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A601, an investigational gene therapy for PKP2-arrhythmogenic cardiomyopathy. This marks Rocket’s fifth RMAT designation, providing expedited FDA review and guidance. The decision stems from Phase 1 trial results that showed encouraging safety and efficacy, with all three patients demonstrating increased PKP2 protein expression, improved heart function, reduced arrhythmias, and better quality of life.
- Philips + Epic: Philips and Epic are integrating Philips’ cardiac ambulatory monitoring and diagnostics services with Epic’s Aura specialty diagnostics suite. The integration offers the broadest cardiac care portfolio available through Aura, enabling providers to order and review ECG results directly within Epic’s EHR system. As a result, the integration eliminates manual data entry, automates patient charting, and reduces administrative burden.
- KFSHRC’s First Robo-Double-LVAD: King Faisal Specialist Hospital and Research Center achieved the world’s first robotic-assisted implantation of two artificial heart pumps for biventricular support. The surgical team used remotely controlled robotic arms to implant two Abbott HeartMate 3 ventricular assist devices in a 61-year-old patient with end-stage HF who was not a transplant candidate. The robotic approach led to lower infection risk and faster recovery. KFSHRC previously performed the world’s first fully robotic heart transplant in 2024.
- HHS Investigates Early Organ Harvesting: The HHS unveiled major organ transplant system reforms following a disturbing HRSA investigation into Kentucky Organ Donor Affiliates (KYDA). The probe found 73 patients with neurological signs incompatible with donation and 28 who may not have been deceased when organ procurement began. HHS Secretary RFK Jr. called the findings “horrifying,” citing cases where hospitals initiated organ procurement despite patients showing signs of life.
- Cardio-Microcurrent Improves HF: Berlin Heals published results in the European Journal of Heart Failure showing significant benefits of its Cardio-Microcurrent (C-MIC) device for heart failure patients. The randomized trial of 70 patients with non-ischemic dilated cardiomyopathy found that C-MIC therapy plus standard treatment improved LVEF by 6.6% versus 1.5% in controls. Additionally, 84% of C-MIC patients improved by at least one NYHA class compared to 15% of controls, with similar improvements in quality of life and walking distance.
|
|
Making the Leap to Outsource Post-Processing
Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
|
|
Identify and Treat Cardiovascular Disease
Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
GE HealthCare Unlocks Real-Time Cardiac Insights, Anywhere, Anytime
Your workstation isn’t the only place to view cardiac images. Tune in to this online webinar on how GE HealthCare’s Zero Footprint Viewer is being used in real clinical settings to access images anywhere, anytime.
|
|
- New Horizons in Structural Heart: TAVR and TMVR rates are rising rapidly, placing more pressure on interventional planning. Tune into this Circle CVI and Radcliffe Cardiology breakout detailing how to leverage modern CT workflows to produce efficient and accurate pre-procedural plans.
- LVAD Therapy Receives 1A Recommendation for Inotrope-Dependent Patients: The U.S. joint societies of the AHA/ACC/HFSA have given LVAD therapy a 1A Recommendation for heart failure patients dependent on intravenous inotropes or who cannot be weaned from temporary mechanical circulatory support. As both the strongest class of recommendation and highest level of evidence, a 1A Recommendation indicates LVAD therapy is supported by strong data and the benefits far outweigh the risks.
- Discover Innovation in Intervention: Explore how the AGENT™ Drug-Coated Balloon from Boston Scientific is advancing U.S.-based treatment options for patients with coronary artery disease. Rx Only. (Sponsored by Boston Scientific)
- Monebo Difference in Comprehensive Cardiac Mapping: Monitoring the heart 24/7 means being in tune with the body’s natural cycles. Read about how Monebo’s approach to cardiac monitoring provides visual representations of a patient’s heart rate, cardiac muscle relaxation, and electrical excitation throughout the day.
- Merge Hemo Expands to Puerto Rico: Merge partnered with Alpha Biomedical to bring Merge Hemo to Puerto Rico, marking the software’s first expansion outside the 50 U.S. states. Read more about the work Merge is doing to expand access to its award winning solutions beyond the United States.
- 5,600 Ways to Improve Your Cardiac Ultrasound Workflow: AI-powered measurements can enhance the way you acquire and interpret cardiac ultrasound. Learn how AI-powered ultrasound can help you overcome everyday limitations in echo. Read Siemens Healthineers’ white paper on how its AI software provides 5,600+ automated measurements to help improve workflow efficiency, consistency, and clinical confidence.
- Vista AI Reduces Patient Backlog: Cardiac MRI is infamous for its complexity and backlogs, but it doesn’t need to be that way. See how Vista Cardiac delivered a 50% reduction in scan time variability, enabling shorter scheduling blocks and eliminating a one-month backlog.
|
|
|
|
|
